Higher Odds of Trial of Labor With Night Float Call System

Share this content:
Higher Odds of Trial of Labor With Night Float Call System
Higher Odds of Trial of Labor With Night Float Call System

MONDAY, Jan. 9, 2017 (HealthDay News) -- Physicians working on a night float call system are more likely to have patients with a prior cesarean delivery undergo trial of labor and achieve vaginal birth, according to a study published in the January issue of the American Journal of Obstetrics & Gynecology.

Lynn M. Yee, M.D., M.P.H., from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues examined the correlation between obstetricians' call schedule and obstetric outcomes in a retrospective cohort study involving women eligible for a trial of labor after cesarean. The authors classified attending obstetrician call schedules as traditional or night float call, which was defined as a schedule in which the provider had clinical responsibilities only for a day or night shift, with no additional responsibilities before or after their period of responsibility.

The researchers found that 37 percent of the 1,502 eligible patients were delivered by physicians in a night float call system. Women cared for by physicians with a night float call schedule were significantly more likely to undergo a trial of labor after cesarean (33.1 versus 16.5 percent) and to achieve a vaginal birth after cesarean (18.7 versus 9.3 percent). After adjustment for confounding variables, these correlations persisted (adjusted odds ratios, 2.64 and 2.17, respectively).

"Using a night float call schedule may be an effective measure to promote a trial of labor after cesarean and vaginal birth after cesarean," the authors write.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »